IVA Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	15 499.00
Gjennomsnittsvolum	40 793.00
Markedsverdi	172.82M
EPS	$0 ( 2024-04-03 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.270
ATR14	$0.0520 (1.58%)

Inventiva S.A. Korrelasjon

10 Mest positive korrelasjoner
CPIX	0.937
PSTX	0.933
SRTS	0.931
NESR	0.93
TKNO	0.926
ENTA	0.924
GTEC	0.923
FULC	0.921
CNDT	0.916
MULN	0.915

10 Mest negative korrelasjoner
XOG	-0.895
VERX	-0.894
HSTM	-0.878
BOCH	-0.868
EPZM	-0.864
CNCE	-0.86
HURN	-0.858
FIZZ	-0.854
IMRX	-0.852
MXIM	-0.847

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Inventiva S.A. Økonomi

Annual	2023
Omsetning:	$17.48M
Bruttogevinst:	$17.50M (100.13 %)
EPS:	$-2.43

FY	2023
Omsetning:	$17.48M
Bruttogevinst:	$17.50M (100.13 %)
EPS:	$-2.43

FY	2022
Omsetning:	$12.18M
Bruttogevinst:	$11.18M (91.83 %)
EPS:	$-1.310

FY	2021
Omsetning:	$4.19M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.270

Financial Reports:

Symbol	Period	Year	Title
IVA	FY	2023	Inventiva S.A. Reports Fiscal Year 2023 Financial Results

Inventiva S.A.

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.